Edward Dempsey, MD

Publications

• • Littler CM, Wehling CA, Wick MJ, Fagan KA, Messing RO, Dempsey EC. Divergent contractile and structural responses of the murine PKC-epsilon null pulmonary circulation to chronic hypoxia Am J Physiol 289: L1083-L1093, 2005.
• • Karoor V, Walchak S, Miller Y, Dempsey EC. Role of Rho in increased migration of pulmonary artery smooth muscle cells in the neprilysin null mouse. Chest 128:582S-583S 2005.
• Rockwell LC, White MM, Dempsey EC, Moore LG. Chronic hypoxia diminishes the proliferative response of guinea pig uterine artery vascular smooth muscle cells in vitro. High Altitude Medicine & Biology (In Press) 2006.
• • Littler CM, Wehling CA, Fagan KA, Messing RO, Dempsey EC. Divergent contractile and structural responses of the murine PKC-epsilon null pulmonary circulation to chronic hypoxia. Chest 128: 620S-621S, 2005
• • Petty TP, Dempsey EC, Collins T, Pluss W, Lipkus I, Cutter GR, Chalmers R, Mitchell A, Weil KC. Impact of customized videotape education on quality of life in patients with chronic obstructive pulmonary disease (model of chronic hypoxic pulmonary hypertension). J Cardiopulmonary Rehab 26:112-117, 2006.
• Kennedy TC, Franklin WA, Prindiville SA, Cook R, Dempsey EC, Keith RL, Hirsch FR, Merrick TA, Shroyer KR, Petty TL, Byers T, Bunn PA, Miller YE. High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia. Lung Cancer 49:187-191, 2005
• Petty TP, Dempsey EC, Collins T, Pluss W, Lipkus I, Cutter GR, Chalmers R, Mitchell A, Weil KC. Impact of customized videotape education on quality of life in patients with chronic obstructive pulmonary disease. J Cardiopulmonary Rehab 26:112-117, 2006.
• Rockwell LC, Dempsey EC, Moore LG. Chronic hypoxia diminishes the proliferative response of guinea pig uterine artery vascular smooth muscle cells in vitro. High Altitude Medicine & Biology 7: 237-244, 2006.
• Case D, Irwin D, Ivestor C, Harral J, Morris K, Roedersheimer M, Imamura M, Patterson A, Carr M, Hagen M, Saavedra M, Crossno J Jr, Dempsey EC, Poirier F, West J, Majka S. Mice deficient in galectin-1 exhibit attenuated physiological responses to chronic hypoxia-induced pulmonary hypertension.Am J Physiol 292: L154-L164, 2007.
• Crossno JT Jr, Reusch JEB, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR, Klemm DJ. Rosiglitazone attenuates pulmonary arterial remodeling but not the development of pulmonary hypertension in response to hypoxia. Am J Physiol (In Press) 2007.
• 7. Dempsey EC and Littler CA.. "Lung disease and protein kinase Cs". Pharmacological Research (Invited review in special issue on 'Protein kinase Cs and their therapeutic potential') (In Press) 2007.
• Irwin D, Helm K, Imamura M, Fagan K, Harral J, Carr M, Young KA, Klemm D, Dempsey EC, West J, Majka S. Hyperoxic exposure decreases the primitive resident lung endothelial precursor population in a murine model of bronchopulmonary dysplasia. Am J Physiol (Revision Requested) 2007.
• Karoor V, Oka M, Walchak S, Hersh L, Miller Y, Dempsey EC. Neprilysin and regulation of mouse pulmonary artery smooth muscle cell phenotype in vitro. Hypertension 61(4): 921-30, 2013.
• Tottempudi PK, Reyland ME, Das M, McMurtry IF, Hoagland KD, Stenmark KR, Dempsey EC. Upstream regulation of protein kinase C-alpha gene expression in bovine pulmonary artery smooth muscle cells. Am J Physiol (Revision Requested) 2007.
• Wick MJ, Wehling CA, Barr E, Voelkel NF, Dempsey EC. Lung neprilysin activity and expression are decreased in a human model of chronic hypoxic pulmonary hypertension. Am J Respir Crit Care Med (In Press) 2007.
• Wick MJ, Wehling CA, Barr E, Voelkel NF, Dempsey EC. Lung neprilysin activity and expression are decreased in a human model of chronic hypoxic pulmonary hypertension. Am J Respir Crit Care Med (Completing Internal Review; Submission Pending) 2007.
• Dempsey EC, Tallman DW, Wheling CA, Karoor V, Fagan KA, Cool CD, Wick MJ, Morris KG, Jr., Le M, Hersh L, Gerard N, Gerard C, Miller YE. Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia. (In Preparation), 2007.
• Ruff LJ, Grever KF, Fagan KA, McMurtry IF, Pettit GR, Dempsey EC. Attenuating effects of bryostatin-1 in an adult murine model of chronic hypoxic pulmonary hypertension (In Preparation), 2007.
• Miller YE, Karoor V, Dempsey EC, Fagan KA. Sleep-disordered breathing, hypoxemia, and cancer mortality. Am J Resp Crit Care Med 187:330-331, 2013.
• Dempsey EC. Neprilysin and Susceptibility to Pulmonary Vascular Disease: Therapeutic Implications and Mechanistic Insights. 2013.
• Wick M, Dempsey EC. Decreased lung neprilysin gene expression in humans with COPD and pulmonary vascular remodeling.
• Wick MJ, Barr EJ, Wehling CA, Miller YE , Voelkel NF, Dempsey EC. Lung neprilysin activity and expression are decreased in a human model of chronic hypoxic pulmonary hypertension. ATS meeting. Am J Respir Crit Care Med:175:A44, 2007.
• Dempsey EC, Cool CD, and Littler CA. "Lung disease and PKCs". Pharmacological Research 55: 545-559, 2007.
• Dempsey EC, Wick MJ, Karoor V, Barr EJ, Tallman DW, Wehling CA, Walchak SJ, Laudi S, Le M, Oka M, Majka S, Cool CD, Fagan KA, Klemm DJ, Hersh LB, Gerard NP, Gerard C, Miller YE. Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia. (Under Review) 2008.
• Dempsey EC. Treatment of pulmonary vascular remodeling with Neprilysin; with Univ Colorado; US Patent application #13/224,124; 2014.
• Karoor V, Irwin DE, Sullivan T, Loomis Z, Hersh LB, Dempsey EC. Neprilysin regulates cytoskeletal protein expression in and phenotype of murine pulmonary artery smooth muscle cells. AJRCCM. ATS and VA Research Day Symposium; Poster presentations 2014.
• Karoor V, Irwin DE, Sullivan T, Loomis Z, Hersh LB, Dempsey EC. Vascular bed specific functions of neprilysin in smooth muscle cells. AJRCCM; Accepted for ATS presentation; 2015.
• Badesch D et al "Endothelin Receptor Antagonists" in Pulmonary Circulation: Diseases and their treatment, Fourth Edition(Editors: A Peacock, R Naeije, L Rubin).
• Case D, Irwin D, Ivestor C, Ivestor C, Harral J, Morris K, Roedersheimer M, Imamura M, Patterson A, Carr M, Hagen M, Saavedra M, Crossno J Jr, Dempsey EC, Poirier F, West J, Majka S. Mice deficient in galectin-1 exhibit attenuated physiological responses to chronic hypoxia-induced pulmonary hypertension. Am J Physiol 292:L154-L164, 2007.
• Karoor V, Irwin DE, Sullivan T, Loomis Z, Hersh LB, Dempsey EC. Vascular bed specific functions of neprilysin in smooth muscle cells. (final preparation) Hypertension 2015.
• Wick MJ, Loomis ZL, Harral J, LE M, Miller YE, Dempsey EC. Neprilysin transgenic mouse with complex overexpression pattern and protection again vascular leak. (In preparation) 2015
• Crossno JT Jr, Reusch JEB, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR, Klemm DJ. Rosiglitazone attenuates pulmonary arterial remodeling in response to hypoxia. Am J Physiol 292: L885-L897, 2007.
• Irwin D, Helm K, Imamura M, Fagan K, Harral J, Carr M, Young KA, Klemm S, Dempsey EC, West J, Majka S. Hyperoxia induced changes in pulmonary microvascular density and endothelial progenitor populations in a murine model of bronchopulmonary dysplasia. Am J Physiol 293: L941-L951, 2007.
• Dempsey EC, Wick MJ, Karoor V, Barr E, Tallman DW, Wehling CA, Walchak S, Laudi S, Le M, Oka M, Majka SM, Cool CD, Fagan KA, Klemm DJ, Hersh L, Gerard N, Gerard C, Miller YE. Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia. Am J Path 174: 782-796, 2009.
• Kittelson KK, Franklin WA, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Hirsch FR, Bunn PA, Miller YE. A randomized phase II chemoprevention trial of 13-cis retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. (In Press) 2009.
• Wick, M.J., Barr, E.J., Wehling, C.A., Cool, Zamora, M., C.D., Miller, Y.E., Hersh, L.B., Voelkel, N.F., Dempsey, E.C. Lung Neprilysin Activity and Expression are Decreased in Humans with COPD and Pulmonary Vascular Remodeling. 2009 Exp. Biol. Meeting, FASEB J. 968, 770.3 (2009)
• Dempsey EC, Wick MJ, Karoor V, Barr E, Tallman DW, Wehling CA, Walchak S, Laudi S, Le M, Oka M, Majka SM, Cool CD, Fagan KA, Klemm DJ, Hersh L, Gerard N, Gerard C, Miller YE. Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia. Am J Path 174: 782-796, 2009.
• Kittelson KK, Franklin WA, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Hirsch FR, Bunn PA, Miller YE. A randomized phase II chemoprevention trial of 13-cis retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. Cancer Prev Res 2(5):440-449, 2009.
• Wick M, Buesing E, Wehling C, Loomis Z, Cool C, Zamora M, Miller Y, Colgan S, Hersh L, Voelkel N, Dempsey EC. Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease. Am J Resp Crit Care Med. Submitted 2/2/2010 (Revision requested) 2010.
• Badesch D, Fox D, Pugliese S, Robinson J, Graham B, Dempsey EC, Bull TM. Endothelin receptor antagonists. Chapter 31. Pulmonary Circulation: Disease and their Treatment, Fourth Edition. Editors: Peacock, Naeije, and Rubin. CRC Press, Taylor & Francis Group, Boca Raton, FL, 2015.
• Karoor V, Irwin DE, Sullivan TM, Loomis Z, Hersh LB, Dempsey EC. Vascular bed specific functions of neprilysin in smooth muscle cells. Am J Respir Crit Care Med 191:A1935, 2015.
• Karoor V, Irwin DE, Sullivan TM, Loomis Z, Hersh LB, Dempsey EC. Sustained Rho activation promotes a synthetic pulmonary artery smooth muscle phenotype in neprilysin null mice. Hypertension, 2015.
• Wick MJ, Loomis ZL, Harral J, LE M, Miller YE, Dempsey EC. Neprilysin transgenic mouse with complex overexpression pattern and protection again vascular leak. Transgenic Research 2015.
• Karoor V, Oka M, Walchak S, Hersh L, Miller Y, Dempsey EC. Neprilysin and regulation of mouse pulmonary artery smooth muscle cell phenotype in vitro. Being submitted 3/26/2010. Circ Res, 2010.
• Fox D, Pugliese S, Robinson J, Graham B, Dempsey EC, Bull TM, Badesch D. Endothelin receptor antagonists. Chapter 31: 1-7. Pulmonary Circulation: Disease and their Treatment, Fourth Edition. Editors: Peacock, Naeije, and Rubin. CRC Press, Taylor & Francis Group, Boca Raton, FL, 2016.
• Dempsey EC. Neprilysin and VIP knockout mice. Part 1: Genetically Manipulated Mouse Models of Pulmonary Vascular Disease and Lung Injury. Drug Discovery Today: Disease Models. (Ed J. Yuan). Elsevier Press (Invited Review) 2010.
• Wick MJ, Loomis ZL, Harral J, LE M, Miller YE, Dempsey EC. Neprilysin transgenic mouse with complex overexpression pattern and protection again vascular leak. Transgenic Research 25 (6): 773-784; DOI 10.1007/s11248-06-9969-x, 2016.
• Karoor V, Fini M, Irwin DE, Sullivan TM, Loomis Z, Hersh LB, Dempsey EC. Sustained Rho activation promotes a synthetic pulmonary artery smooth muscle phenotype in neprilysin null mice. Arteriosclerosis, Thrombosis, and Vascular Biology, (Invited Revision) 2016.
• Karoor V, Loomis Z, Sullivan TM, Hersh LB, Irwin D, Dempsey EC. Sustained activation of RhoGTPases promote a synthetic pulmonary artery smooth muscle cell phenotype in neprilysin null mice. Am J Respir Crit Care Med, (In Press) 2016.
• Karoor V, Fini M, Irwin DE, Sullivan TM, Loomis Z, Hersh LB, Dempsey EC. Sustained Rho activation promotes a synthetic pulmonary artery smooth muscle phenotype in neprilysin null mice. Arteriosclerosis, Thrombosis, and Vascular Biology, (In Press) 2017.
• Wick MJ, Harral JW, Loomis ZL, Dempsey EC. An optimized Evans blue protocol to assess vascular leak in the mouse, Journal of Visualized Experiments (Jove) (#57037: In Press) 2017.
• Karoor V, Le M, Merrick D, Dempsey EC, Miller Y. VEGFR-2 targeted chemoprevention of murine lung tumors. Cancer Prev Res. (In Press) 2010.
• Wick M, Miller Y, Dempsey EC. Neprilysin peptidase-independent complex formation in pulmonary artery smooth muscle cells (Abstract). Accepted for presentation at the 2010 EB meeting in Anaheim, California.
• Karoor V, Oka M, Walchak S, Miller Y, Dempsey EC. Neprilysin regulates PASMC phenotype and PDGFR signaling in mice (Abstract). Accepted for presentation at the 2010 ATS meeting in New Orleans, Louisiana
• Karoor V, Fini M, Irwin DE, Sullivan TM, Loomis Z, Hersh LB, Dempsey EC. Sustained Rho activation promotes a synthetic pulmonary artery smooth muscle phenotype in neprilysin null mice. Arteriosclerosis, Thrombosis, and Vascular Biology 38:154-163, 2018.
• Wick MJ, Harral J, Loomis ZL, Dempsey EC. Assessing vascular leak in mouse. Journal of Visualized Experiments (Jove) 139, 1-9. DOI 10.3791/57037, 2018.
• Treatment of pulmonary vascular remodeling with neprilysin. Dempsey EC and Univ of Colorado. Patent # US 9,950,044 B2. Issued April 24, 2018.
• Immune cells in heart failure. Strassheim D, Dempsey E, Gerasimovskaya E, Stenmark K, Karoor V. Invited review, submitted 2018, J Immunology Research, 2019.
• Co-localization of metastatic colon cancer and disseminated Fusobacterium necrophorum: is there a cause and effect. Chan ED, King M, Hurley H, Davidson KR, Schlepp M, Dempsey EC, Barron MA, Frey A. submitted 2018, Accepted for American Thoracic Society meeting, 2019.
• Wick MJ, Barr EJ, Wehling CA, Loomis ZL, Cool CD, Miller YE, Hersh LB, Voelkel NF, Dempsey EC. Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease (Abstract). Accepted for presentation at the 2010 ATS meeting in New Orleans, Louisiana.
• Karoor V, Le M, Merrick D, Dempsey E, Miller Y. VEGFR-2 targeted chemoprevention of murine lung tumors. Cancer Prev Res. 3: 1141-1147, 2010.
• Wick M, Buesing E, Wehling C, Loomis Z, Cool C, Zamora M, Miller Y, Colgan S, Hersh L, Voelkel N, Dempsey EC. Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 183:330-340, 2011
• Dempsey EC, Loomis Z, Wick M. Recent advances in lung neuropeptide biology using neprilysin and VIP knockout mice. Part 1: Genetically Manipulated Mouse Models of Pulmonary Vascular Disease and Lung Injury. Drug Discovery Today: Disease Models. (Ed J. Yuan). Elsevier Press (In Press) 2011.
• Karoor V, Oka M, Walchak S, Hersh L, Miller Y, Dempsey EC. Neprilysin regulates pulmonary artery smooth muscle cell phenotype through a PDGF receptor dependent mechanism. (Resubmitted 3-28-11; J Biol Chem) 2011.
• Wick MJ, Loomis ZL, Buesing EJ, Wehling CA , Cool CD, Hersh LB, Voelkel NF, Dempsey EC. Decreased lung neprilysin gene expression in humans with COPD and pulmonary vascular remodeling. Session: Lung Physiology: Pulmonary Hypertension. 2011 Experimental Biology Meeting, Washington, D.C., Tues. April 12, 2011. FASEB J (In Press) 2011.
• Wick, MJ, Loomis, ZL, Dempsey, EC. Neprilysin and pulmonary vascular remodeling in COPD: Peptidase-independent complex formation. Session: Pulmonary Circulation: Vascular Smooth Muscle. 2011 American Thoracic Society Meeting, Denver, CO, Monday, May 16, 2011. Am J Respir Crit Care Med (In Press) 2011.
• Karoor V , Oka M, Walchak SJ, Hersh LB, Miller YE, Dempsey EC , Neprilysin regulates mouse pulmonary artery smooth muscle cell phenotype. Session: Pulmonary Circulation: Vascular Smooth Muscle. 2011 American Thoracic Society Meeting, Denver, CO, Monday, May 16, 2011. Am J Respir Crit Care Med (In Press) 2011.
• Wick M, Buesing E, Wehling C, Loomis Z, Cool C, Zamora M, Miller Y, Colgan S, Hersh L, Voelkel N, Dempsey EC. Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 183:330-340, 2011
• Dempsey EC, Loomis Z, Wick M. Recent advances in lung neuropeptide biology using neprilysin and VIP knockout mice. Part 1: Genetically Manipulated Mouse Models of Pulmonary Vascular Disease and Lung Injury. Drug Discovery Today: Disease Models. (Ed J. Yuan). 7:1-9, 2011.
• Strassheim D, Karoor V, Nijmeh H, Weston P, Lapel M, Schaack J, Sullivan T, Dempsey EC, Stenmark KR, Gerasimovskaya E. c-Jun, Foxo3a, and c-Myc Transcription Factors are Key Regulators of ATP-Mediated Angiogenic Responses in Pulmonary Artery Vasa Vasorum Endothelial Cells. Cells. 2020 Feb 11;9(2):416. doi: 10.3390/cells9020416. PMID: 32054096; PMCID: PMC7072142.
• Karoor V, Le M, Merrick D, Dempsey E, Miller Y. Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR dependent mechanism. Cancer Prev Res (In Press), 2012.
• Dempsey E, Strassheim D, Karoor V. Impaired vascular function with age and RhoGTPase. Aging (Albany NY). 2020 Jan 6;12(1):1-2. doi: 10.18632/aging.102739. Epub 2020 Jan 6. PMID: 31905168; PMCID: PMC6977650.
• King M, Hurley H, Davidson KR, Dempsey EC, Barron MA, Chan ED, Frey A. The Link between < i>Fusobacteria< /i> and Colon Cancer: a Fulminant Example and Review of the Evidence. Immune Netw. 2020 Aug 4;20(4):e30. doi: 10.4110/in.2020.20.e30. PMID: 32895617; PMCID: PMC7458797.
• Karoor V, Oka M, Walchak S, Hersh L, Miller Y, Dempsey EC. Neprilysin and regulation of mouse pulmonary artery smooth muscle cell phenotype in vitro. Hypertension (Revision Completed), 2012.
• Maron BA, Choudhary G, Goldstein RL, Garshick E, , Jankowich M, M.D.,Tucker TJS, LaCerda KA, Hattler B, Dempsey EC, Sadikot RT, Shapiro S, Rounds SI, Goldstein RH. Tadalafil for Chronic Obstructive Pulmonary Disease-Pulmonary Hypertension: A Multicenter, Placebo-Controlled Randomized Trial. Seven year project; completed and manuscript under review; Ann Am Thorac Soc.
• Wick MJ, Loomis ZL, Buesing EJ, Wehling CA , Cool CD, Hersh LB, Voelkel NF, Dempsey EC. Decreased lung neprilysin gene expression in humans with COPD and pulmonary vascular remodeling. Session: Lung Physiology: Pulmonary Hypertension. Experimental Biology Meeting, Washington, D.C., FASEB J 2011 and Aspen Lung Conference 2011.
• Wick, MJ, Loomis, ZL, Hersh, LB, Dempsey, EC. Mechanisms that decrease human neprilysin gene expression in cigarette smoke-induced pulmonary vascular disease. Experimental Biology Meeting, San Diego, CA, Monday, April 23, 2012. FASEB J 2012.
• Karoor V, Le M, Merrick D, Dempsey EC, Fagan KA, Miller YE. Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR dependent mechanism. Cancer Prev Res 5:1061-1071, 2012.
• Karoor V, Oka M, Walchak S, Hersh L, Miller Y, Dempsey EC. Neprilysin regulates pulmonary artery smooth muscle cell phenotype through a PDGF Receptor Dependent Mechanism. Hypertension (In Press; Ms#199588R3 epublished Jan 2013).
• Karoor V, Strassheim D, Sullivan T, Verin A, Umapathy NS, Dempsey EC, Frank DN, Stenmark KR, Gerasimovskaya E. The short-chain fatty acid butyrate attenuates pulmonary vascular remodeling and inflammation in hypoxia-induced pulmonary hypertension. Int J Mol Sci. 2021 Sep 14;22(18):9916. doi: 10.3390/ijms22189916. PMID: 34576081 .
• • Karoor V, Swindle D, Pak DI, Strassheim D, Fini MA, Dempsey E, Stenmark KR, Hassell K, Nuss R, Buehler PW, Irwin. Evidence supporting a role for circulating macrophages in the regression of vascular remodeling following sub-chronic exposure hemoglobin plus hypoxia. Pulm Circ. 2021 Nov 5;11(4):20458940211056806. doi: 10.1177/20458940211056806. eCollection 2021 Oct-Dec.
• Miller YE, Karoor V, Dempsey EC, Fagan KA. Sleep-disordered breathing, hypoxemia, and cancer mortality. Am J Resp Crit Care Med 187:330-331, 2013.
• Karoor V, Loomis Z, and Dempsey EC. Loss of NEP Induces a Synthetic Pulmonary Artery Smooth Muscle Cell Phenotype Associated with Decreased Expression of Contractile Proteins. Submitted for 2013 American Thoracic Society Meeting.
• Application #13/224,126 with Univ of Colo; Dempsey EC. Neprilysin to Treat Pulmonary Hypertension

Practice Locations

• University of Colorado Hospital

Specialty Information

• Internal Medicine, Board Certification (1986)
• Pulmonary Disease, Board Certification (1988)
• Critical Care Medicine, Board Certification (1989)

• Lungs and Breathing - Pulmonary Hypertension
• Lungs and Breathing